Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Enovis (ENOV)

Enovis CEO Matt Trerotola to retire once successor is named; search underway

Neutral Impact 4 of 5 leadership Written later

Enovis CEO Matt Trerotola told the Board on February 25, 2025, that he intends to retire, effective when the Board appoints and his successor assumes the CEO role. The Board is working with an executive search firm to find the next CEO, and the filing does not name a candidate or a timeline for the appointment.

Key points

  • Trerotola notified the Board of his retirement intention on February 25, 2025, and the company announced it in a February 26, 2025 press release.
  • He will stay on as an employee and Executive Advisor to the company and his successor for one year after the successor is appointed, under a Retirement and Transition Agreement not yet executed.
  • The Board is working with an executive search firm to identify the next CEO, described as a growth-oriented MedTech leader.
  • Trerotola will address the transition on the fourth quarter and full-year 2024 results call scheduled for 8:30 a.m. ET on February 26, 2025.

The filing

CompanyEnovis (ENOV)
Form8-K, current report
Filed with the SECFeb 26, 2025, 6:10 AM ET
Accession number0001193125-25-035746

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.